Your AI-Trained Oncology Knowledge Connection!

Harriet Kluger, MD

home / authors / harriet-kluger-md

Articles

The Toxicity Profile of Concurrent Nivolumab and Ipilimumab

October 4th 2014

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.

How Immunotherapies are Changing the Treatment of Melanoma

Harriet Kluger, MD

March 12th 2014

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.

Toxicities Associated With Immunotherapies

Harriet Kluger, MD

February 11th 2014

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the toxicities associated with immunotherapies.

The Changing Landscape of Immunotherapies for the Treatment of Melanoma

Harriet Kluger, MD

January 18th 2014

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, comments on the changing landscape of immunotherapies for the treatment of melanoma.

The Difference Between Blocking PD-1 and PD-L1 in Melanoma

Harriet Kluger, MD

November 27th 2013

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the difference between blocking PD-1 and PD-L1 in melanoma.